Skip to Main Content

Newly published data reveal in greater depth the problem Sanofi Pasteur’s Dengvaxia vaccine poses to children who have never experienced a dengue infection.

The findings, first revealed by the company last November, were the basis of an April decision by a World Health Association expert panel to recommend the vaccine only be given to children who have tested positive for a prior dengue infection. There is no such test at the moment.


Despite the publication in the New England Journal of Medicine, a Sanofi official said the company remains committed to finding a way to allow the vaccine to be used safely to reduce dengue’s enormous health care burden.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.